Market Research Report
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein), By Technology (MAb, rDNA), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases), By Region - Forecast (2016-2021)
|Published by||IndustryARC||Product code||422456|
|Published||Content info||146 Pages
Delivery time: 1-2 business days
|Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein), By Technology (MAb, rDNA), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases), By Region - Forecast (2016-2021)|
|Published: September 14, 2016||Content info: 146 Pages||
Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, growing prevalence of chronic diseases among aging population are the prime growth drivers of global remicade biosimilar market. In addition, increase in adoption of remicade biosimilar in emerging economies such as China, India and others, will create new opportunities for global remicade biosimilar market. However, higher cost of the research and development, and stringent government regulations are the key restraints for global remicade biosimilar market.
Geographically European dominated global remicade biosimilar market because of favourable regulatory policies designed by the European Medical Association, high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing prevalence of chronic diseases in developing nations such as China, and India in this region. Among all the application, oncology segment has the highest market share in global remicade biosimilar market due to higher prevalence of cancer patients.
This report identifies the global remicade biosimilar market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global remicade biosimilar market.
Remicade Biosimilar Market, By Type: Recombinant Non-Glycosylated Protein, Recombinant Glycosylated Protein, and Peptides
Remicade Biosimilar Market, By Technology: Monoclonal Antibodies (MAb) Technology, Recombinant DNA Technology (rDNA), Nuclear Magnetic Resonance (NMR) Technology, Chromatography, Electrophoresis, Mass Spectrometry, Western Blotting, and Bioassay
Remicade Biosimilar Market, By Service: Contract Research and Manufacturing Services (CRAMS), and Clinical Trials
The report has focused study on remicade biosimilar market by basis of application such as: Blood Disorders, Oncology Diseases, Chronic and Autoimmune Diseases, Growth Hormone Deficiencies, and Others
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
Teva Pharmaceutical Industries Ltd.
Synthon Pharmaceuticals, Inc.
LG Life Sciences
More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"